Venture Wire, Staff Reporters, July 07, 2010
Obstetric device developer CerviLenz Inc. has named Federica O’Brien to the newly created positions of chief financial officer and chief operating officer.
O’Brien was previously a director of life sciences at RSM McGladrey, an assurance, tax and consulting firm. She also served as a senior financial executive at biotechnology companies Cardiokine Inc. and Barrier Therapeutics Inc. and Internet software and services company Infonautics Inc.
O’Brien will play a key role in the company’s funding round planned for next year, according to a CerviLenz representative.
Last year, CerviLenz raised $4 million in Series A-1 financing to finish ongoing clinical trials and begin commercialization. Investors include Arboretum Ventures, Chrysalis Ventures and North Coast Angel Fund.
Based in Chagrin Falls, Ohio, CerviLenz was founded in early 2008 and is developing a device to measure the length of a woman’s cervix during pregnancy as a predictor of pre-term birth risk.